A vision for the future? by Baum, M
INTRODUCTION 
Despite local treatment (surgery ± radiotherapy) for patients
diagnosed with early breast cancer, approximately 30–40% of
such patients will develop a distant recurrence of disease within
10 years of initial diagnosis (Early Breast Cancer Trialists’
Collaborative Group, 1998; Rutqvist, 1998). Consequently,
systemic adjuvant therapy is recommended for the majority of
women alongside primary local treatment, with the aim of
improving long-term survival. Over the past 10–15 years, there
has been significant progress in the development of adjuvant ther-
apies for patients with early breast cancer. Furthermore, there has
been a dramatic fall of about 30% in breast cancer mortality rates
in the UK between 1987 and 1997 (Peto, 2000). This is not attrib-
uted solely to adjuvant therapy but rather signifies an integrated
approach to diagnosis, and the evaluation and adoption of new
therapies. 
ENDOCRINE THERAPIES IN BREAST CANCER 
In recent years, much has been elucidated in terms of the role of
the endogenous hormones in the pathogenesis of breast cancer
(Figure 1). Indeed, reflecting on the previous St. Gallen meeting,
significant progress has been made in evaluating endocrine thera-
pies for use in early breast cancer (Early Breast Cancer Trialists’
Collaborative Group, 1998). At that time, tamoxifen (Nolvadex™)
had undoubtedly been established as the standard for adjuvant
endocrine therapy (immediately after local therapy) in hormone-
sensitive pre- and postmenopausal patients with early breast
cancer, and had also been suggested to be effective in the
prevention of hormone-responsive breast cancers. Furthermore,
luteinizing hormone releasing hormone (LHRH) agonists were
recognized to be effective in advanced disease in pre- and peri-
menopausal women, and trials in early disease had been initiated.
More specifically, a number of large trials involving the LHRH
agonist, goserelin (Zoladex™), in early breast cancer had
completed patient recruitment, with the first data awaited.
Anastrozole (Arimidex™), an aromatase inhibitor, had been
shown to be effective in advanced disease as second-line therapy
for postmenopausal patients, first-line trials versus tamoxifen in
the advanced disease setting had completed recruitment and the
ATAC (Arimidex, tamoxifen, alone or in combination) trial to
assess the efficacy and tolerability of Arimidex (anastrozole) in
early disease had also been enrolling patients for 18 months.
Additionally, ICI 182,780 (Fulvestrant™) had completed phase I
and II studies, ultimately defining this agent as an oestrogen
receptor (ER) down-regulator. This new endocrine agent was, at
that time, a new candidate entering the metastatic disease setting. 
Having now proven effective and well tolerated in advanced
disease, in comparative or non-comparative trials, it is considered
likely that each of these therapies could provide new treatment
options across the spectrum of breast cancer disease. Emerging
results from clinical trials indicate that these agents may be set
to challenge clinical practice and to improve outcomes in the
early disease setting that have traditionally been achieved using
tamoxifen or chemotherapy. 
TAMOXIFEN – THE STANDARD ENDOCRINE
THERAPY 
Tamoxifen has long been established as an effective treatment
option in postmenopausal patients with hormone-sensitive early
breast cancer, providing a clear survival benefit when prescribed
for 2–5 years following surgery (Early Breast Cancer Trialists’
Collaborative Group, 1992; 1998), with 5 years of treatment
providing the most benefit. In prevention of breast cancer, tamox-
ifen has been reported to provide a 49% reduction in the incidence
of invasive breast cancer, in women at high risk from the disease,
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has been associated with treatment resistance, tumour flare and an
increased incidence of thromboembolic events and long-term risk
for endometrial cancer (Fisher et al, 1996). The effects of 
tamoxifen on the endometrium (postmenopausal bleeding and
vaginal discharge) are an additional concern. These adverse 
effects are probably due to the partial agonist properties of tamox-
ifen, which may limit its potential utility as an antioestrogen
(Katzenellenbogen et al, 1997). Moreover, although they are a
concern, the risk of long-term adverse effects is more acceptable in
patients receiving tamoxifen for management of the disease than
when it is advocated for prevention of breast cancer. 
OPTIMIZING THERAPY FROM PRE- TO
POSTMENOPAUSAL SETTINGS 
The choice of adjuvant therapy for women with early breast cancer
is heavily influenced by a number of prognostic and predictive
factors (see Jonat, p 1), most notably the hormone-receptor status
of the tumour – both ER and progesterone receptor (PgR). 
Perhaps one of the key issues relating to endocrine therapies
involves the treatment of ER-negative tumours. Current opinion
suggests that there is no role for endocrine manipulation in ER-
negative tumours. However, there are potentially three controver-
sial roles for using endocrine agents in these patients: 
● For secondary prevention – of contralateral breast cancer
(Fisher et al, 1998) 
● For protecting fertility in ER-negative women who are
receiving chemotherapy – shutting down the ovary using
LHRH agonists may protect future ovarian function (Boccardo
et al, 1994; Teslik and Horejsi, 1997; Jonat, 1998) 
● Oestradiol itself is genotoxic, thus the action of aromatase
inhibitors (or possibly LHRH agonists) in reducing circulating
levels of oestradiol may have an impact in terms of prevention
on ER-positive and ER-negative cases. In contrast, tamoxifen
has not yet proven to be effective in ER-negative tumours,
though this could be a consequence of its unique mode of
action associated with receptor binding (Fisher et al, 1998). 
For treatment of hormone-sensitive primary breast cancer,
depriving the tumour by way of blockade or suppression of
oestrogen synthesis has proven valuable in prolonging survival
(Early Breast Cancer Trialists’ Collaborative Group, 1996).
Successful achievement of oestrogen-suppression is influenced by
the patient’s menopausal status. In premenopausal women, the
main source of oestrogen is provided by the ovaries. However,
after the menopause, oestradiol is synthesized peripherally
through aromatization of androgens (Masamura et al, 1994)
(Figure 1). Thus, in manipulating endocrine involvement in breast
cancer, we have to take these different mechanisms of oestrogen
production into account and consider whether it is possible to
optimize efficacy and tolerability by using the available therapies
alone or in combination. In optimizing endocrine therapy for early
breast cancer, we need to evaluate the newer agents in terms of
their efficacy in advanced disease, their tolerability as judged
against the standard and whether or not the dosing regimens are
convenient. 
Pre-/perimenopausal setting 
Goserelin provides reversible medical ovarian suppression by
reducing serum oestradiol levels to postmenopausal values within
21 days of the start of therapy, thus offering premenopausal
patients an attractive alternative to conventional irreversible
ovarian ablation by oophorectomy (or irradiation). In pre-/peri-
menopausal women, adjuvant ovarian ablation plays an important
role in enhancing disease-free and overall survival in patients with
early breast cancer (Early Breast Cancer Trialists’ Collaborative
Group, 1996), with the induction of amenorrhoea serving as a
significant prognostic factor in these patients. Recent data from
ongoing international adjuvant trials indicate that goserelin may be
used in a number of different clinical situations involving pre-/
perimenopausal patients with early breast cancer. 
The results of the ZEBRA (‘Zoladex’ Early Breast Cancer
Research Association) trial have demonstrated that goserelin
monotherapy is as effective as cyclophosphamide/methotrexate/5-
fluorouracil (CMF) in pre-/perimenopausal patients with ER-
positive, node-positive, early breast cancer (Kaufmann, 2001).
Although chemotherapy is thought to induce its effect partly by
ovarian suppression, it would be expected to have an additional
cytotoxic effect and thus provide further benefits compared with
goserelin therapy in premenopausal patients with ER-positive
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Figure 1 Role of hormones and endocrine therapies in pre- and postmenopausal women with early breast cancer tumours. However, this does not appear to be true and there is no
reasonable explanation for this observation. This suggests that
goserelin is a viable alternative to chemotherapy following local
therapy in these patients. Although cytotoxic chemotherapy may
remain the first-choice treatment in some patients, its efficacy has
been largely attributed to its effects on ovarian suppression, with
achievement of amenorrhoea an indicator of this effect (Powles,
1998). However, achievement of amenorrhoea with chemotherapy
can be highly variable (30–90%) and dependent on a number of
factors, including the regimen used and the age of the patient
(Bines et al, 1996). 
Goserelin could offer benefits when used not only as
monotherapy but alternatively as an adjunct to chemotherapy
(ZIPP trial: ‘Zoladex’ in premenopausal patients). Irrespective of
standard therapy (standard therapy = surgery and/or radiotherapy
and/or chemotherapy and/or tamoxifen), the addition of goserelin
in unselected patients produces a further benefit. Furthermore,
when selecting groups, in those who are chemo-naive and those
who are ER-positive the results are more profound (Houghton 
et al, 2000). The sub-group analyses for this study should be 
available by the end of the year. Other international trials (see
Jonat, p 1) have shown that goserelin is also effective in improv-
ing recurrence-free survival when combined with tamoxifen
after cyclophosphamide/adriamycin/5-fluorouracil (CAF) chemo-
therapy (Davidson et al, 1999), or when combined with tamoxifen
as an alternative to CMF chemotherapy (Boccardo et al, 2000;
Jakesz et al, 2001; Jonat et al, 2000). 
Postmenopausal setting 
For the first time, large-scale trials with anastrozole have demon-
strated the superiority of an endocrine agent over tamoxifen 
for treating postmenopausal patients with hormone-sensitive
metastatic breast cancer (Buzdar et al, 2000; see Buzdar, p 6).
Moreover, based on data from the advanced disease setting, and as
predicted from its pharmacology, anastrozole has a more desirable
tolerability profile than tamoxifen. Unlike the concerns that have
previously been raised regarding the incidence of thromboem-
bolism with tamoxifen – which is exacerbated when used after
initial chemotherapy (Fisher et al, 1996; Pritchard et al, 1996) –
anastrozole has been associated with significantly fewer thrombo-
embolic events in trials in advanced disease. Furthermore, fewer
patients experienced vaginal bleeding events with anastrozole
compared with tamoxifen, a finding that could be indicative of
anastrozole having less effect than tamoxifen on the endometrium
(Nabholtz et al, 2000; Bonneterre et al, 2000). Demonstration of
the superior efficacy and improved tolerability of anastrozole
compared with tamoxifen in advanced disease gives the hope that
these findings will translate to the early breast cancer setting. The
ATAC trial has now completed recruitment, with over 9300
patients from 380 centres in 21 countries, and represents the
largest adjuvant trial of its kind to date. A recent review by the
Data Monitoring Committee recommended that the trial should
continue and revealed that there was no excess of the predicted
adverse events in any of the trial arms, thus the safety data to date
look very promising. The predicted number of events that would
allow the first formal efficacy analysis is expected to be reached
during 2001. 
Finally, ICI 182,780 is another major innovation in endocrine
therapy on the horizon for postmenopausal women. ICI 182,780
lacks the partial agonist activity characteristic of tamoxifen 
(see Robertson, p 11). This potent anti-oestrogen is highly effec-
tive in down-regulating ER protein and ultimately blocking cell
proliferation. The first data from ongoing trials of ICI 182,780 as a
second-line therapy in advanced disease have been collated and
they confirm that it is at least as effective and well tolerated as
anastrozole and may offer a further potential therapeutic option for
the adjuvant breast cancer setting in the future (Robertson et al,
2000). 
A VISION FOR THE FUTURE 
Based on these new findings, it is important to consider the poten-
tial impact of these endocrine agents on treatment guidelines for
breast cancer today, and in the very near future. There have been a
number of treatment recommendations to date, most notably those
outlined by the International Consensus Panel on the Treatment of
Primary Breast Cancer (Goldhirsch et al, 1998). These guidelines
were based on evidence from clinical trials available at that time,
when the use of LHRH agonists in the treatment of early breast
cancer was still under investigation. 
As successful ovarian suppression is known to improve out-
comes in premenopausal women, substantial change in the manage-
ment of premenopausal women with ER-positive tumours is likely,
particularly with the data emerging on LHRH agonists. The greatest
challenge will be in establishing precisely how to use these agents.
Although there are few comparative data available for goserelin in
combination with chemotherapy, given the value of goserelin as
monotherapy, and the increasing appreciation of the importance of
achieving ovarian suppression, there may be a strong case for
combining goserelin with chemotherapy on a routine basis. 
At the last St. Gallen meeting the aromatase inhibitors were not
even considered. While data for adjuvant therapy with anastrozole
are not yet available, the data in advanced disease are very encour-
aging, proving it to be a potent, effective and well-tolerated agent
which is at least as effective as tamoxifen, the current standard. If
these benefits are shown by the ATAC trial to translate into the
early disease setting, anastrozole is likely to be included in the
consensus statement by the next St. Gallen meeting. 
CONCLUSION 
The vision for the future is exciting and we are now in a position to
review the recommendations right across the spectrum (Figure 2).
For pre- and perimenopausal patients, it is crucial to recognize the
importance of successful ovarian suppression. In light of the posi-
tive data reported from international trials, goserelin should be
incorporated into the consensus to allow patients to be offered an
informed choice of therapies. 
Pre-/perimenopausal patients with ER-positive tumours may
currently be offered treatment with: tamoxifen; tamoxifen and
chemotherapy; or ovarian suppression (with or without tamox-
ifen). For the postmenopausal patient, tamoxifen remains the 
standard for ER-positive patients with a good prognosis, and
chemotherapy combined with tamoxifen for patients with a poor
prognosis. We also await with interest the potential of anastrozole,
with or without tamoxifen, for the next St. Gallen consensus 3
years from now. 
Although both chemotherapy and tamoxifen have undoubtedly
had a significant impact on the outcome of patients with early
breast cancer, there is still room for improvement in treatment
modalities, and it is hoped that the emerging data for endocrine
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menopausal women. These newer, effective and well-tolerated
endocrine agents – goserelin, anastrozole and ICI 182,780 – are
likely to have an impact on and show improvements over tamox-
ifen treatment, which has been the standard treatment for breast
cancer in postmenopausal women for the past 25 years. 
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Figure 2 Vision for the future of treatment across the patient spectrum: (A)
pre-/perimenopausal patients (B) postmenopausal patients 